Aging is the biggest risk-factor for cancers, heart disease, Alzheimer’s, and other detrimental indications. We’re on a mission to therapeutically reverse aging to prevent and treat these diseases.
We tackle the complexity of aging with deep-learning-guided, multiomics drug design that optimizes thousands of drug interactions implicated in longevity, safety, and systemic deliverability.
Our drug discovery and design platform, CANDO, is a robust IP-generating engine benchmarked and validated in hundreds of applications across dozens of indications. With Mansarover, we're excited to utilize its multiomics scale to design new rejuvenating therapies for longevity and age-related diseases. Read a few selected publications on our platform here:
As a drug discovery company, we're always looking for new and exciting partnership opportunities with companies in longevity biotech. Don't hesitate to reach out if your company is working on complex mechanisms of aging, multiple difficult targets, or transcription factors/biologics therapies in need of improved deliverability.